| DC46680 |
5'-O-TBDMS-dA |
5'-O-TBDMS-dA is a modified nucleoside and can be used to synthesize DNA or RNA. |
|
| DC46681 |
5'-O-TBDMS-dG |
5'-O-TBDMS-dG is a modified nucleoside. 5'-O-DMT-2'-O-TBDMS-rI can be used in the synthesis of deoxyribonucleic acid or nucleic acid. |
|
| DC46682 |
5'-O-TBDMS-dT |
5'-O-TBDMS-dT is a nucleoside with protective and modification effects. |
|
| DC46683 |
5-O-TBDMS-N4-Benzoyl-2-deoxycytidine |
5-O-TBDMS-N4-Benzoyl-2-deoxycytidine is a modified nucleoside. 5-O-TBDMS-N4-Benzoyl-2-deoxycytidine can be used in the synthesis of deoxyribonucleic acid or nucleic acid. |
|
| DC46684 |
Cytidine-5'-triphosphate |
Cytidine 5′-triphosphate (5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii. |
|
| DC46685 |
Uridine triphosphate 13C9,15N2 sodium |
Uridine triphosphate 13C9,15N2 (UTP 13C9,15N2) sodium is a labeled Uridine triphosphate sodium. Uridine triphosphate sodium can be used in nucleic acid synthesis. |
|
| DC46826 |
Fanotaprim |
Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis. |
|
| DC46827 |
(-)-Irofulven |
(-)-Irofulven (MGI 114), an Illudin S analog, is a DNA alkylating agent. (-)-Irofulven inhibits the replication of DNA, induces tumor cells apoptosis, and has potent antitumor activity. |
|
| DC46828 |
Fostroxacitabine bralpamide |
Fostroxacitabine bralpamide (MIV-818) is an orally active Troxacitabine-based nucleotide prodrug. Fostroxacitabine bralpamide has anticancer effects. |
|
| DC46829 |
Cotosudil |
Cotosudil is a ROCK kinase inhibitor, which can be used for glaucoma or ocular hypertension research. |
|
| DC46830 |
Intoplicine dimesylate |
Intoplicine (RP 60475) dimesylate, an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine dimesylate strongly binds DNA (KA = 2 x 105 /M) and thereby increases the length of linear DNA. |
|
| DC46831 |
T-2513 hydrochloride |
T-2513 hydrochloride is a selective topoisomerase I inhibitor. T-2513 hydrochloride binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death. |
|
| DC46943 |
Dalpiciclib
Featured
|
Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable CDK4/6 inhibitor with comparable potencies against CDK4 (IC50=12.4 nM) and CDK6 (IC50=9.9 nM). Dalpiciclib exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated tumor-suppressor retinoblastoma protein (Rb) and inducing G1 cell cycle arrest. |
|
| DC46944 |
Ipivivint |
Ipivivint (SM08502), a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer. |
|
| DC46945 |
Avotaciclib |
Avotaciclib (BEY1107) is an orally active cyclin dependent kinase 1 (CDK1) inhibitor. Avotaciclib can be used for the research of cancer. |
|
| DC46946 |
PF-07220060
Featured
|
PF-07220060 is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. |
|
| DC47042 |
Mipicoledine |
Mipicoledine is a potential neuro-alkylating agent for study of glioblastoma and metastatic cancers involving the central nervous system. |
|
| DC47043 |
Ocarocoxib |
Ocarocoxib, a potent COX-2 (cyclooxygenase-2) inhibitor, is a non-steroidal anti-inflammatory for veterinary use. |
|
| DC47048 |
Rebamipide mofetil
Featured
|
Rebamipide mofetil is an orally active prodrug of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner. |
|
| DC47109 |
Cimpuciclib |
Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic. |
|
| DC47130 |
CDK5-IN-1 |
CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research. |
|
| DC47131 |
ATR inhibitor 4
Featured
|
ATR inhibitor 4 (compound 121) is a potent ATR inhibitor. ATR inhibitor 4 has antitumor activity. |
|
| DC47159 |
Tetroxoprim |
Tetroxoprim is an antimicrobial DHFR inhibitor. |
|
| DC47205 |
Eltenac |
Eltenac, a non-steroidal anti-inflammatory drug (NSAID), is a COX inhibitor. Eltenac shows IC50 of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood. |
|
| DC47211 |
TC-E 5001 |
TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively. |
|
| DC47219 |
8-Aminoadenosine |
8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits mRNA synthesis. 8-Aminoadenosine blocks Akt/mTOR signaling and induces autophagy and apoptosis in a p53-independent manner. 8-Aminoadenosine has antitumor activity. |
|
| DC47236 |
Cirtuvivint |
Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research. |
|
| DC47269 |
Samuraciclib
Featured
|
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects. |
|
| DC47325 |
Huanglongmycin N |
Huanglongmycin N is a DNA topoisomerase I inhibitor (EC50 = 14 μM). |
|
| DC47377 |
PLK1-IN-2 |
PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM. |
|
